Diarrhea associated with afatinib: an oral ErbB family blocker
Gastrointestinal (GI) adverse events (AEs) are frequently observed in patients receiving EGF
receptor (EGFR; also known as HER1 or ErbB1) tyrosine kinase inhibitor therapy. GI AEs are …
receptor (EGFR; also known as HER1 or ErbB1) tyrosine kinase inhibitor therapy. GI AEs are …
[HTML][HTML] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
MS Gordon, DS Mendelson, M Gross… - Investigational new …, 2013 - Springer
Background This trial evaluated the safety, tolerability and maximum tolerated dose (MTD) of
afatinib, a novel ErbB Family Blocker. Methods In this open-label, dose-escalation Phase I …
afatinib, a novel ErbB Family Blocker. Methods In this open-label, dose-escalation Phase I …
[HTML][HTML] A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours
A Suder, JE Ang, F Kyle, D Harris, S Rudman… - European Journal of …, 2015 - Elsevier
Background This phase I study evaluated afatinib, an irreversible ErbB family blocker, plus
paclitaxel in patients with advanced solid tumours likely to express human epidermal growth …
paclitaxel in patients with advanced solid tumours likely to express human epidermal growth …
[HTML][HTML] A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
J Marshall, J Hwang, FALM Eskens, H Burger… - Investigational new …, 2013 - Springer
Summary Background A Phase I study to determine the maximum tolerated dose (MTD) and
pharmacokinetics of afatinib (BIBW 2992), a novel irreversible ErbB Family Blocker …
pharmacokinetics of afatinib (BIBW 2992), a novel irreversible ErbB Family Blocker …
Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours
S Wind, M Schmid, J Erhardt, RG Goeldner… - Clinical …, 2013 - Springer
Abstract Background and Objective Afatinib is a potent, irreversible, ErbB family blocker in
clinical development for the treatment of a variety of solid tumours. This study evaluated the …
clinical development for the treatment of a variety of solid tumours. This study evaluated the …
[HTML][HTML] Relationship between plasma concentrations of afatinib and the onset of diarrhea in patients with non-small cell lung cancer
H Yokota, K Sato, S Sakamoto, Y Okuda, M Asano… - Biology, 2021 - mdpi.com
Simple Summary Higher afatinib plasma concentrations have been reported to be
associated with the severity of diarrhea; however, the specific target plasma concentration of …
associated with the severity of diarrhea; however, the specific target plasma concentration of …
[HTML][HTML] A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus …
JB Vermorken, S Rottey, E Ehrnrooth, K Pelling… - Annals of oncology, 2013 - Elsevier
Abstract Background In this phase Ib, dose-escalation study, the oral irreversible ErbB family
blocker afatinib (BIBW 2992) was combined with cisplatin (Cadila Healthcare Ltd …
blocker afatinib (BIBW 2992) was combined with cisplatin (Cadila Healthcare Ltd …
[HTML][HTML] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
D Schnell, S Buschke, H Fuchs, D Gansser… - Cancer chemotherapy …, 2014 - Springer
Purpose Afatinib, an oral irreversible ErbB family blocker, undergoes minimal metabolism by
non-enzyme-catalysed adduct formation with proteins or nucleophilic small molecules and is …
non-enzyme-catalysed adduct formation with proteins or nucleophilic small molecules and is …
Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers
P Stopfer, K Marzin, H Narjes, D Gansser… - Cancer chemotherapy …, 2012 - Springer
Purpose To investigate the pharmacokinetics, metabolism and tolerability of afatinib (BIBW
2992), an oral irreversible ErbB family blocker, in healthy male volunteers. Methods In this …
2992), an oral irreversible ErbB family blocker, in healthy male volunteers. Methods In this …
Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Dermatologic adverse events (AEs) are frequently observed in patients receiving EGF
receptor (EGFR; also known as ErbB1) tyrosine kinase inhibitor therapy. The impact of these …
receptor (EGFR; also known as ErbB1) tyrosine kinase inhibitor therapy. The impact of these …